TRUPLEX: Enhanced Variant Identification by High-Efficiency Duplex Sequencing
A method developed by scientists at the Sanger Institute that links both DNA strands in one read so that every construct has an internal error check. This removes the need to sequence multiple PCR duplicates and dramatically reduces overall read depths required to identify variants.
TruPlex, is a method developed by scientists at the Sanger Institute that links both DNA strands in one read so that every construct has an internal error check. This removes the need to sequence multiple PCR duplicates and dramatically reduces overall read depths required to identify variants.
TruPlex works by incorporating a first strand of DNA and the complement of its second strand into a single construct so both can be read in a sequencing by synthesis reaction. Optionally, differences between the sequence of the first and second repeats can also be read simultaneously where ambiguous bases, can be identified as low-quality base calls and discarded while the matched reads can be retained for analysis.
- Recover data from samples where DNA availability is limited or fragmented:
– Circulating Tumour Cells/DNA
– Formalin-Fixed Paraffin-Embedded
- Confidently identify rare cell population mutants in heterogeneous tissues, for example, minor cell populations in a bulk tumour.
- Efficient and easy to scale: 10-20x better yield than equivalent methods.
How it works: Direct repeats are produced by circularisation, nicking and extending the crick strand to incorporate a copy in the same molecule.
Highly specific detection of rare variants. For example, monitoring minimal residual disease, identifying rare resistance mutations in cancer patients, single cell sequencing or in depth analysis of small sample biopsies.
Current duplex sequencing methods are inefficient owing to the separate tagging and amplification of each strand. TruPlex links both strands, which are then amplified together in a single molecule. This improves efficiencies and makes the approach easier to scale.
Priority patent applications filed in the US and UK.
The Wellcome Sanger Institute is offering non-exclusive licenses to its IPR.